ADT's acquisition of Origin AI brings presence-sensing technology under the home security company's umbrella.

The $170 million acquisition brings Origin’s AI sensing technology and more than 200 patents into ADT’s platform, with commercialization of new offerings expected in 2027.

“This five-year commercial agreement reflects the value and global scalability of our AI sensing platform,” said Omar Khan, Executive Vice President and Chief Business Officer of ADT.   “Partnering ...

“Joining ADT allows our AI platform to scale across millions of homes, combining enhanced situational awareness with unmatched monitoring expertise. Together, we will move the industry to continuous, ...

BOCA RATON, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) today announced its inclusion into the S&P SmallCap 600® Index, effective prior to the opening of trading this morning, Feb. 9, ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

ADT is a defensive, cash-generative business trading below intrinsic value, assuming it increases its ROIC. State Farm and Apollo, holding ~27% combined, may sell shares, potentially pressuring ADT’s ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

Patients who received ADT for 3 months or 9 months had worse overall survival than those treated for 36 months. For men with prostate cancer treated with definitive radiotherapy, the benefit derived ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

Androgen deprivation therapy (ADT), also called hormone therapy, is a common treatment for metastatic prostate cancer. It works by starving the cancer of testosterone, which fuels the tumor’s growth.

ADT remains undervalued versus newly listed peer Verisure, supported by strong revenue growth, improving profitability, and a high share of recurring revenue. ADT's business is supported by ...